fashion -WSS

fashion

author：comprehensive 2025-10-02 21:04:35 - browse：4228

The corporate offices of Massachusetts General Brigham hospitals in Assembly Square in Somerville. Lane Turner/Globe Staff

The severing of ties between two of Boston’s biggest health care giants has placed one of the nation’s largest health care systems in the position of figuring out how, exactly, to fill a new hole in its oncology services, at a time when cancer care is changing rapidly.

Earlier this month, Dana-Farber Cancer Institute surprised the medical community and even its partner, Brigham and Women’s Hospital, when it announced that it would end their nearly 30-year collaboration. The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians.

Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives. The two parties had been in discussions about extending their contract for months when the split was announced. “The decision was made by the Farber. It was announced. Now, we just have to plan forward,” she said. Klibanski shared her views on the split at a meeting with Boston Globe opinion editors on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Cancer, immunology, HIV research ensnared in fetal tissue politics

hotspot

WSS

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Texas board proposes rules on abortion law emergency exemption

Medicare Advantage insurers pressure Biden for bigger payments

Chinese researcher claims birth of first gene

6 surprising facts about sugar

Mirador, a new biotech startup, launches with $400 million

hotspot

fashion

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

State Dept. review finds Biden bears some blame for Afghanistan failures

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Tori Bowie and the unacceptable rates of Black maternal death

Boston's new lab space is opening empty

How one medical school became remarkably diverse

Steward Health Care expansion into Malta flopped

Medicare details structure of new drug price negotiation program

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

leisure time

EPA limits use of carcinogenic gas for sterilizing medical devices

Asbestos ban is immediate, but health effects will linger for decades

Medicare coverage of Wegovy, once blocked, now looks possible

Yancopoulos of Regeneron works to expand Dupixent success

Cancer, immunology, HIV research ensnared in fetal tissue politics

WuXi out of biotech trade group, U.S. and China relations to blame

leisure time

explore

hotspot

explore